These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22139032)

  • 21. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
    Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
    Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
    Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
    Hansen TF; Christensen Rd; Andersen RF; Sørensen FB; Johnsson A; Jakobsen A
    Br J Cancer; 2013 Sep; 109(5):1243-51. PubMed ID: 23922111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
    Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
    Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
    BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
    Berger MD; Stintzing S; Heinemann V; Cao S; Yang D; Sunakawa Y; Matsusaka S; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Zhang W; Cremolini C; Falcone A; Loupakis F; Lenz HJ
    Clin Cancer Res; 2018 Feb; 24(4):784-793. PubMed ID: 29208668
    [No Abstract]   [Full Text] [Related]  

  • 29. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Crea F; Fornaro L; Paolicchi E; Masi G; Frumento P; Loupakis F; Salvatore L; Cremolini C; Schirripa M; Graziano F; Ronzoni M; Ricci V; Farrar WL; Falcone A; Danesi R
    Ann Oncol; 2012 May; 23(5):1207-1213. PubMed ID: 21926398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
    Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
    Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.
    Roh SA; Park IJ; Yoon YS; Kwon YH; Chung JH; Kim TW; Cho DH; Lim BH; Kim SK; Kim SY; Kim YS; Kim JC
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1705-14. PubMed ID: 27177629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
    Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Berger MD; Yamauchi S; Cao S; Hanna DL; Sunakawa Y; Schirripa M; Matsusaka S; Yang D; Groshen S; Zhang W; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Lonardi S; Cremolini C; Falcone A; Heinemann V; Loupakis F; Stintzing S; Lenz HJ
    Eur J Cancer; 2017 May; 77():13-20. PubMed ID: 28347919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
    Chionh F; Gebski V; Al-Obaidi SJ; Mooi JK; Bruhn MA; Lee CK; Chüeh AC; Williams DS; Weickhardt AJ; Wilson K; Scott AM; Simes J; Hardingham JE; Price TJ; Mariadason JM; Tebbutt NC
    Sci Rep; 2022 Jan; 12(1):1238. PubMed ID: 35075138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
    Suzuki T; Shinozaki E; Osumi H; Nakayama I; Ota Y; Ichimura T; Ogura M; Wakatsuki T; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):307-313. PubMed ID: 31065729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).
    Zinser-Sierra JW; Rodríguez-Ramírez S; Villalobos-Valencia R; Ramírez-Márquez M
    Drugs R D; 2011; 11(2):101-11. PubMed ID: 21679003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer.
    Kim JC; Ha YJ; Roh SA; Choi EY; Yoon YS; Kim KP; Hong YS; Kim TW; Cho DH; Kim SY; Kim YS
    Br J Cancer; 2013 May; 108(9):1862-9. PubMed ID: 23579219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
    Kocakova I; Melichar B; Kocak I; Bortlicek Z; Büchler T; Dusek L; Petruzelka L; Kohoutek M; Prausová J; Finek J; Mohelnikova-Duchonova B; Vyzula R
    Anticancer Res; 2015 Jun; 35(6):3455-61. PubMed ID: 26026110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
    Di Salvatore M; Pietrantonio F; Orlandi A; Del Re M; Berenato R; Rossi E; Caporale M; Guarino D; Martinetti A; Basso M; Mennitto R; Santonocito C; Mennitto A; Schinzari G; Bossi I; Capoluongo E; Danesi R; de Braud F; Barone C
    Oncotarget; 2017 Mar; 8(10):16887-16898. PubMed ID: 28129643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.